Lycia Therapeutics: director Rieflin William JL received 44,840 shares

What happened

• Rieflin William JL, a director of Lycia Therapeutics, received awards of derivative securities totaling 44,840 shares: 24,840 shares on Aug 11, 2026 and 20,000 shares on Oct 22, 2026. Each award shows an acquisition price of $0.00 and is reported as a derivative.

Key details

• Transaction dates and prices: Aug 11, 2026 — 24,840 shares at $0.00 (A); Oct 22, 2026 — 20,000 shares at $0.00 (A).
• Shares owned after the transaction: Not reported in the filing.
• Footnotes from the filing:
  • F1: The Aug 11, 2026 transaction occurred prior to the issuer's Section 12 registration in connection with the initial public offering and is reported pursuant to Rule 16a-2(a).
  • F2: The 24,840-share award vests 1/48 of the total award monthly over 4 years, with the first tranche vested on Sep 6, 2026, subject to continued service.
  • F3: The 20,000-share award vests 100% on Oct 22, 2027, subject to continued service.
• Filing date: Oct 26, 2026. The filing does not state whether it was late.

Why it may matter

• These transactions are grants of derivative securities (option/award grants) with specified vesting schedules; the filing does not show any sale or market trade of underlying shares. A filing does not show why the insider traded or why the company acted.